Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2019, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 15, 27, 10, 41, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Keratoconjunctivitis Sicca (Dry Eye) - Overview
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products
Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Universities/Institutes, H2 2019
Table 8: Products under Development by Companies, H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 14: Products under Development by Universities/Institutes, H2 2019
Table 15: Number of Products by Stage and Target, H2 2019
Table 16: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019
Table 19: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 20: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 21: Number of Products by Stage and Route of Administration, H2 2019
Table 22: Number of Products by Stage and Molecule Type, H2 2019
Table 23: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, H2 2019
Table 24: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, H2 2019
Table 25: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, H2 2019
Table 26: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, H2 2019
Table 27: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Table 28: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, H2 2019
Table 29: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2019
Table 30: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allosterix Ltd, H2 2019
Table 31: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allysta Pharmaceuticals Inc, H2 2019
Table 32: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Apidel SA, H2 2019
Table 33: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2019
Table 34: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aurinia Pharmaceuticals Inc, H2 2019
Table 35: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aviara Pharmaceuticals Inc, H2 2019
Table 36: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Avizorex Pharma SL, H2 2019
Table 37: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AxeroVision Inc, H2 2019
Table 38: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Azura Ophthalmics Ltd, H2 2019
Table 39: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Bessor Pharma LLC, H2 2019
Table 40: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by BRIM Biotechnology Inc, H2 2019
Table 41: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2019
Table 42: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Table 43: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Dhp Korea Ltd, H2 2019
Table 44: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2019
Table 45: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Emerald Bioscience Inc, H2 2019
Table 46: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by EyGen Ltd, H2 2019
Table 47: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Feldan Therapeutics Inc, H2 2019
Table 48: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by GL Pharm Tech Corp, H2 2019
Table 49: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Glaukos Corp, H2 2019
Table 50: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Glia LLC, H2 2019
Table 51: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Table 52: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Huons Co Ltd, H2 2019
Table 53: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2019
Table 54: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Icure Pharmaceutical Inc, H2 2019
Table 55: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Ipsen SA, H2 2019
Table 56: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by IVIEW Therapeutics Inc, H2 2019
Table 57: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2019
Table 58: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kowa Co Ltd, H2 2019
Table 59: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2019
Table 60: Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Kv1.3 Therapeutics, H2 2019
List of Figures
Figure 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Molecule Types, H2 2019
